Scynexis Secures $214M BARDA Contract for Antifungal SCY-247 Development
Event summary
- Scynexis awarded a BARDA contract worth up to $214M for SCY-247 development.
- Initial funding of $18.5M to advance SCY-247 into Phase 2 trials for invasive candidiasis.
- Contract may extend up to 10 years, covering two indications: treatment and prevention of invasive fungal infections.
- SCY-247 has Orphan, QIDP, and Fast Track designations from the FDA.
- Funding is non-dilutive, with BARDA covering eligible costs under a cost-share arrangement.
The big picture
The BARDA contract underscores the strategic importance of addressing drug-resistant fungal infections, a growing public health threat. Scynexis's ability to secure non-dilutive funding for SCY-247 strengthens its pipeline diversification, particularly as it advances SCY-770 for ADPKD. The deal highlights the increasing collaboration between biotech firms and government agencies to tackle critical unmet medical needs.
What we're watching
- Funding Execution
- How Scynexis will allocate the $214M BARDA funding across SCY-247's development phases.
- Pipeline Diversification
- Whether the BARDA partnership will enhance Scynexis's long-term value proposition beyond SCY-770.
- Regulatory Momentum
- The pace at which SCY-247 advances through Phase 2 trials and potential NDA submission.
Related topics